Model for the synthesis of clinical effectiveness evidence | Odds ratio (95% CrI) |
---|---|
M1: Fixed-effect model considering three treatments: IVIG/IVIGAM vs. albumin vs. no treatment, with covariate on duration of IVIG therapy. Relative effectiveness estimate reported for IVIG/IVIGAM vs. albumin for a duration of therapy of three days. | 0.75 (0.58, 0.96) |
M2: Random-effects model considering three treatments: IVIG/IVIGAM vs. albumin vs. no treatment, no covariates. Relative effectiveness estimate reported for IVIG/IVIGAM vs. albumin. | 0.68 (0.16, 1.83) |
M3: Random-effects model considering two treatments: IVIG/IVIGAM vs. albumin or no treatment, with covariate on Jadad score. Relative effectiveness estimate reported assuming a Jadad score of 5. | 0.83 (0.18, 2.13) |
M4a: Random-effects model considering two treatments: IVIG/IVIGAM vs. albumin/no treatment, with covariate representing . Relative effectiveness estimate reported assuming a sample size of 339 patients* | 0.92 (0.23, 2.10) |
M4b: Random-effects model considering two treatments: IVIG or IVIGAM vs. albumin or no treatment, with covariates representing . Relative effectiveness estimate assumes an infinitely large sample size* | 1.27 (0.25, 3.17) |